Freddy Ali, MD
Psychiatry · Philadelphia, PANPI 1851504922
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 47.0% of the total. 2025 is the largest year on record at $66,722, more than ten times the $24 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $341.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$50K
- Alkermes, Inc.$30K
- E.r. Squibb & Sons, L.L.C.$16K
- Teva Pharmaceuticals USA, Inc.$9K
- AbbVie$480
- Johnson & Johnson$376
- plus $1K from 9 others
What the payments were for
- Consulting fees$30,73029%
- Speaking & faculty fees$58,21155%
- Travel & lodging$10,0879%
- Food & beverage$7,7597%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 107 | $50,148 |
| Alkermes, Inc. | 72 | $29,773 |
| E.r. Squibb & Sons, L.L.C. | 31 | $15,566 |
| Teva Pharmaceuticals USA, Inc. | 13 | $9,423 |
| AbbVie | 21 | $480 |
| Johnson & Johnson | 15 | $376 |
| Otsuka America Pharmaceutical, Inc. | 20 | $370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $343 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $125 |
| Sunovion Pharmaceuticals Inc. | 4 | $80 |
| Indivior Inc. | 1 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Almatica Pharma LLC | 1 | $17 |
| Corium, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,800 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 15 | $23,652 |
| CaplytaLumateperone Tosylate | 14 | $22,487 |
| Effexor XrVenlafaxine Hcl | 12 | $11,043 |
| Clozapine | 100 | $6,233 |
| Seroquel XrQuetiapine Fumarate | 12 | $5,562 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 36 | $4,641 |
| Lurasidone Hcl | 13 | $3,738 |
| Fluphenazine Hcl | 23 | $3,202 |
| Aripiprazole | 36 | $2,500 |
| KlonopinClonazepam | 12 | $1,731 |
| Olanzapine | 108 | $1,671 |
| Buspirone Hcl | 73 | $1,620 |
| Quetiapine Fumarate | 123 | $1,607 |
| Duloxetine Hcl | 83 | $1,591 |
| Haloperidol | 45 | $1,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $29,773 | $23,65215 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $343 | $22,48714 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $9,423 | $77614 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $64688 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.